To whom it may concern,

February 5, 2026

Company name: ExaWizards Inc.
Name of representative: Makoto Haruta,
Representative Director and President, CEO
(TSE Code No.4259)
Inquiries: Tomoaki Maekawa,
Executive Officer, Corporate Management
Division Manager, CFO

Notice Regarding Clinical Trial Notification Submission by Subsidiary for AI-Powered Cognitive Function Diagnostic Support Application (SaMD)

The Company announces that ExaMD Inc. (hereinafter "ExaMD"), a wholly owned subsidiary, has submitted the clinical trial notification to the Pharmaceuticals and Medical Devices Agency (PMDA) for the commencement of a clinical trial in Japan (hereinafter "the Clinical Trial") for its "AI-Powered Cognitive Function Diagnostic Support Application (SaMD)" (hereinafter "the Application"). The Application was designated as a priority review product by the Ministry of Health, Labour and Welfare (MHLW) on February 6, 2025.

1. Overview of the Subsidiary

Company Name	ExaMD Inc.
Location	4-2-8 Shibaura, Minato-ku, Tokyo, 5F
Name and title of Representative	Representative Director, Koji Hazama
Business Description	Planning, development, sales, and alliance of products and services using multi-modal AI technology to solve social issues related to healthcare
Capital	50 million yen

2. Overview of Clinical Trial

The Clinical Trial will be conducted to verify the effectiveness of the Device, which classifies subjects as either "cognitively normal" or "suspected cognitive decline" based on approximately one minute of free conversation. The target sample size is 100 cases or fewer, with a subject enrollment period of three months, made possible by ExaMD's distinctive approach.

The primary endpoint is the accuracy rate of binary classification into "cognitively normal" and "suspected cognitive decline." The secondary endpoint evaluates the concordance rate between the MMSE score estimated by the Application and the actual measured MMSE score. As a safety endpoint, the type, frequency, severity, and causal relationship of adverse events occurring during examination with the Application will be monitored and evaluated.

3. Future Outlook

Clinical trial costs associated with this matter are incorporated into the investment policy for the second half and the upward revision of operating income announced in the second quarter earnings release for the fiscal year ending March 31, 2026. There is no revision to the full year consolidated financial forecast for the fiscal year ending March 31, 2026. The impact on subsequent fiscal years is currently under review, and the Company will promptly disclose any matters requiring disclosure as they arise.